Solid 1Q for Novo eclipsed by Schultz's surprise exit

Novo Nordisk has raised its full year guidance for 2015 on the back of a strong first quarter performance and the successful IPO spin-out of its IT unit.

More from Alimentary/Metabolic

More from Therapy Areas